International Patent: USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH VEGF SIGNALING PATHWAY INHIBITOR AND IMMUNOTHERAPEUTIC AGENT FOR TREATING TUMORS

GENEVA, Aug. 21 -- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/079097) for “USE OF ANTI-HER3 ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH VEGF SIGNALING PATHWAY INHIBITOR AND IMMUNOTHERAPEUTIC AGENT FOR TREATING TUMORS”. With publication no. WO/2026/171227, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 45/06

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....